|
1.
|
Hartgrink HH, Putter H, Klein Kranenbarg
E, Bonenkamp JJ and van de Velde CJ: Value of palliative resection
in gastric cancer. Br J Surg. 89:1438–1443. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Ishizone S, Maruta F, Saito H, Koide N,
Sugiyama A, Nakayama J and Miyagawa S: Efficacy of S-1 for patients
with peritoneal metastasis of gastric cancer. Chemotherapy.
52:301–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Sadeghi B, Arvieux C, Glehen O, et al:
Peritoneal carcinomatosis from non-gynecologic malignancies:
results of the EVOCAPE 1 multicentric prospective study. Cancer.
88:358–363. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kodera Y, Yamamura Y, Shimizu Y, et al:
Peritoneal washing cytology: prognostic value of positive findings
in patients with gastric carcinoma undergoing a potentially
curative resection. J Surg Oncol. 72:60–64. 1999. View Article : Google Scholar
|
|
5.
|
Bando E, Yonemura Y, Takeshita Y, et al:
Intraoperative lavage for cytological examination in 1,297 patients
with gastric carcinoma. Am J Surg. 178:256–262. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Sakuramoto S, Sasako M, Yamaguchi T, et
al: Adjuvant chemotherapy for gastric cancer with S-1, an oral
fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kubota T: The role of S-1 in the treatment
of gastric cancer. Br J Cancer. 98:1301–1304. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Koizumi W, Narahara H, Hara T, et al: S-l
plus cisplatin versus S-l alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Kobayashi O, Konishi K, Kanari M, et al:
Unusual survival for more than 2 years with peritoneal metastases
of gastric cancer. Gastric Cancer. 5:47–50. 2002.PubMed/NCBI
|
|
10.
|
Kai K, Kitajima Y, Hiraki M, et al:
Quantitative double-fluorescence immunohistochemistry (qDFIHC), a
novel technology to assess protein expression: a pilot study
analyzing 5-FU sensitive markers thymidylate synthase,
dihydropyrimidine dehydrogenase and orotate phosphoribosyl
transferases in gastric cancer tissue specimens. Cancer Lett.
258:45–54. 2007.
|
|
11.
|
Ishikawa M, Miyauchi T and Kashiwagi Y:
Clinical implications of thymidylate synthetase, dihydropyrimidine
dehydrogenase and orotate phosphoribosyl transferase activity
levels in colorectal carcinoma following radical resection and
administration of adjuvant 5-FU chemotherapy. BMC Cancer.
8:1882008. View Article : Google Scholar
|
|
12.
|
Tokunaga Y, Sasaki H and Saito T: Clinical
role of orotate phosphoribosyl transferase and dihydropyrimidine
dehydrogenase in colorectal cancer treated with postoperative
fluoropyrimidine. Surgery. 141:346–353. 2007. View Article : Google Scholar
|
|
13.
|
Japanese Gastric Cancer Association:
Japanese Classification of Gastric Carcinoma, 2nd English edition.
Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Bonenkamp JJ, Songun I, Hermans J and van
de Velde CJ: Prognostic value of positive cytology findings from
abdominal washings in patients with gastric cancer. Br J Surg.
83:672–674. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi
K, Mitachi Y and Taguchi T: Late phase II study of novel oral
fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1
M otastat potassium) in advanced gastric cancer patients. Eur J
Cancer. 34:1715–1720. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Koizumi W, Kurihara M, Nakano S and
Hasegawa K: Phase II study of S-1, a novel oral derivative of
5-fluorouracil, in advanced gastric cancer. Oncology. 58:191–197.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Esquivel J, Vidal-Jove J, Steves MA and
Sugarbaker PH: Morbidity and mortality of cytoreductive surgery and
intraperitoneal chemotherapy. Surgery. 113:631–636. 1993.PubMed/NCBI
|
|
18.
|
Jacquet P and Sugarbaker PH:
Peritoneal-plasma barrier. Cancer Treat Res. 82:53–63. 1996.
View Article : Google Scholar
|
|
19.
|
Mori T, Fujiwara Y, Yano M, Tamura S,
Yasuda T, Takiguchi S and Monden M: Experimental study to evaluate
the usefulness of S-1 in a model of peritoneal dissemination of
gastric cancer. Gastric Cancer. 6(Suppl 1): 13–18. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Yamagata S, Nakata B and Hirakawa K:
Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may
be effective against peritoneal dissemination in gastric cancer.
Oncol Rep. 12:973–978. 2004.
|
|
21.
|
Ichikawa W and Sasaki Y: Challenges in
predicting the clinical outcome in S-1-based chemotherapy for
gastric cancer patients. Int J Clin Oncol. 13:206–211. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Kuramochi H, Hayashi K, Uchida K, et al:
5-Fluorouracil-related gene expression levels in primary colorectal
cancer and corresponding liver metastasis. Int J Cancer.
119:522–526. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Sarela AI, Miner TJ, Karpeh MS, Coit DG,
Jaques DP and Brennan MF: Clinical outcomes with laparoscopic stage
M1, unresected gastric adenocarcinoma. Ann Surg. 243:189–195. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Saito H, Yamada Y, Tsujitani S and
Ikeguchi M: Clinicopathologic characteristics of gastric cancer
patients who underwent noncurative gastrectomy with long-term
survival. Langenbecks Arch Surg. 394:99–103. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Sakamoto E, Nagase H, Kobunai T, Oie S and
Oka T, Fukushima M and Oka T: Orotate phosphoribosyltransferase
expression level in tumors is a potential determinant of the
efficacy of 5-fluorouracil. Biochem Biophys Res Commum.
363:216–222. 2007. View Article : Google Scholar
|
